Matches in SemOpenAlex for { <https://semopenalex.org/work/W2589204583> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W2589204583 endingPage "18" @default.
- W2589204583 startingPage "18" @default.
- W2589204583 abstract "18 Background: Most patients with metastatic breast cancer (MBC) are treated with chemotherapy and/or targeted therapy with varying toxicity profiles. Experience with adverse events (AE) may vary and factor into subsequent treatment decisions. As newer agents and combinations become available, it becomes increasingly important to understand which AEs impact treatment decisions. Methods: The objective was to assess patient experience with AEs and preferences for future treatments. Following focus groups and pretests, an online survey was released by breast cancer organizations to recruit patients with MBC. The survey assessed the impact of experiences on future treatment choices and measured preferences via conjoint analysis (CA). Results: A total of 551 respondents completed the online survey. Among the AEs studied to assess their impact on either treatment stops or breaks, neutropenia topped the list, particularly for a required break. Fatigue, hand and foot syndrome, diarrhea, joint pain and peripheral neuropathy (PN) were high for chosen stops. Five AEs (fatigue, alopecia, diarrhea, PN, neutropenia) were studied extensively. Almost all respondents report experiencing fatigue, ~80% experienced alopecia, and ~66% each of the other 3 AEs. For each AE, the majority of respondents reported their prior experience would not impact a future decision involving the same AE; about 1/3 report they’d be more likely to take a treatment with the same AE; 8% to 18% would be less likely to take a treatment with the same AE. CA was also used to assess influence of the 5 AEs on future decisions. Within the tested ranges of likelihood, severity and duration, alopecia had the highest impact; PN, diarrhea, and neutropenia were in the middle; and fatigue was lowest. Further analysis is ongoing and final results will include differences in patient subgroups. Conclusions: This information informs priorities for development of new therapies allowing additional attention on AEs that matter most to patients. In addition, these results may generate discussion and consideration of patient preferences in conversations about care and treatment selection." @default.
- W2589204583 created "2017-03-03" @default.
- W2589204583 creator A5028764986 @default.
- W2589204583 creator A5070621547 @default.
- W2589204583 creator A5072015843 @default.
- W2589204583 creator A5084458085 @default.
- W2589204583 date "2012-12-01" @default.
- W2589204583 modified "2023-10-18" @default.
- W2589204583 title "Impacts of toxicity on patient treatment choices for metastatic breast cancer." @default.
- W2589204583 doi "https://doi.org/10.1200/jco.2012.30.34_suppl.18" @default.
- W2589204583 hasPublicationYear "2012" @default.
- W2589204583 type Work @default.
- W2589204583 sameAs 2589204583 @default.
- W2589204583 citedByCount "2" @default.
- W2589204583 countsByYear W25892045832015 @default.
- W2589204583 countsByYear W25892045832017 @default.
- W2589204583 crossrefType "journal-article" @default.
- W2589204583 hasAuthorship W2589204583A5028764986 @default.
- W2589204583 hasAuthorship W2589204583A5070621547 @default.
- W2589204583 hasAuthorship W2589204583A5072015843 @default.
- W2589204583 hasAuthorship W2589204583A5084458085 @default.
- W2589204583 hasConcept C121608353 @default.
- W2589204583 hasConcept C126322002 @default.
- W2589204583 hasConcept C134018914 @default.
- W2589204583 hasConcept C143998085 @default.
- W2589204583 hasConcept C1862650 @default.
- W2589204583 hasConcept C197934379 @default.
- W2589204583 hasConcept C2775930923 @default.
- W2589204583 hasConcept C2777063308 @default.
- W2589204583 hasConcept C2779802037 @default.
- W2589204583 hasConcept C2779901536 @default.
- W2589204583 hasConcept C29730261 @default.
- W2589204583 hasConcept C530470458 @default.
- W2589204583 hasConcept C555293320 @default.
- W2589204583 hasConcept C71924100 @default.
- W2589204583 hasConceptScore W2589204583C121608353 @default.
- W2589204583 hasConceptScore W2589204583C126322002 @default.
- W2589204583 hasConceptScore W2589204583C134018914 @default.
- W2589204583 hasConceptScore W2589204583C143998085 @default.
- W2589204583 hasConceptScore W2589204583C1862650 @default.
- W2589204583 hasConceptScore W2589204583C197934379 @default.
- W2589204583 hasConceptScore W2589204583C2775930923 @default.
- W2589204583 hasConceptScore W2589204583C2777063308 @default.
- W2589204583 hasConceptScore W2589204583C2779802037 @default.
- W2589204583 hasConceptScore W2589204583C2779901536 @default.
- W2589204583 hasConceptScore W2589204583C29730261 @default.
- W2589204583 hasConceptScore W2589204583C530470458 @default.
- W2589204583 hasConceptScore W2589204583C555293320 @default.
- W2589204583 hasConceptScore W2589204583C71924100 @default.
- W2589204583 hasIssue "34_suppl" @default.
- W2589204583 hasLocation W25892045831 @default.
- W2589204583 hasOpenAccess W2589204583 @default.
- W2589204583 hasPrimaryLocation W25892045831 @default.
- W2589204583 hasRelatedWork W144521535 @default.
- W2589204583 hasRelatedWork W2037999876 @default.
- W2589204583 hasRelatedWork W2070780645 @default.
- W2589204583 hasRelatedWork W2403269090 @default.
- W2589204583 hasRelatedWork W2411890706 @default.
- W2589204583 hasRelatedWork W2589453077 @default.
- W2589204583 hasRelatedWork W2603750384 @default.
- W2589204583 hasRelatedWork W2979892935 @default.
- W2589204583 hasRelatedWork W3181412252 @default.
- W2589204583 hasRelatedWork W377899687 @default.
- W2589204583 hasVolume "30" @default.
- W2589204583 isParatext "false" @default.
- W2589204583 isRetracted "false" @default.
- W2589204583 magId "2589204583" @default.
- W2589204583 workType "article" @default.